Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Has Average Price Target of $100.86 According to Brokerages

Key Points

• Analysts maintain a positive outlook: Tarsus Pharmaceuticals has a “Moderate Buy” consensus rating from 10 brokerages, with an average 12-month price target of $100.86.
• Insiders have been selling shares: Company insiders sold 48,031 shares worth approximately $4.0 million over the past three months, while institutional investors own about 90.01% of the stock.
• Recent financial results were mixed: Tarsus reported quarterly revenue of $173.91 million, exceeding estimates, but its adjusted loss of $0.43 per share was wider than analysts expected. The stock opened at $74.20, below the analyst consensus target.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $100.86.

A number of research firms have issued reports on TARS. Guggenheim decreased their target price on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a research report on Tuesday, July 21st. HC Wainwright reaffirmed a "buy" rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, August 12th. The Goldman Sachs Group assumed coverage on Tarsus Pharmaceuticals in a research note on Thursday, September 24th. They set a "buy" rating and a $116.00 price target for the company. Finally, Barclays assumed coverage on Tarsus Pharmaceuticals in a report on Wednesday, September 16th. They issued an "overweight" rating and a $110.00 price objective for the company.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Elizabeth Lin sold 3,180 shares of the business's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $87.50, for a total value of $278,250.00. Following the sale, the insider owned 1,590 shares of the company's stock, valued at $139,125. The trade was a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the completion of the sale, the director directly owned 94,487 shares in the company, valued at approximately $7,405,891.06. This trade represents a 11.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 48,031 shares of company stock valued at $4,004,227 over the last three months. 9.64% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC raised its position in shares of Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock worth $35,000 after buying an additional 291 shares in the last quarter. Farther Finance Advisors LLC grew its position in Tarsus Pharmaceuticals by 851.6% during the third quarter. Farther Finance Advisors LLC now owns 590 shares of the company's stock worth $46,000 after buying an additional 528 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock worth $50,000 after acquiring an additional 558 shares during the last quarter. State of Wyoming bought a new position in Tarsus Pharmaceuticals in the 2nd quarter worth about $103,000. Finally, Rockefeller Capital Management L.P. increased its stake in Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock worth $105,000 after acquiring an additional 172 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Up 3.0%

Tarsus Pharmaceuticals stock opened at $74.20 on Friday. The firm has a 50 day moving average price of $75.09 and a 200-day moving average price of $67.90. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a twelve month low of $53.89 and a twelve month high of $91.53. The company has a market capitalization of $3.66 billion, a P/E ratio of -68.07 and a beta of 0.44.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. The company had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.65 million. As a group, equities analysts predict that Tarsus Pharmaceuticals will post -4.19 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company's portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus' lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.